MYRIAD GENETICS INC — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
On October 19, 2026, Myriad entered a definitive agreement to sell its Prenatal Health business (Prequel, Foresight, SneakPeek, FirstGene tests) to Labcorp for $210 million cash plus inventory value, expected to close by early 2027. Q3 2026 revenue was $202.7M (down 1% YoY); Cancer Care Continuum and Mental Health revenue $163.4M (up 1% YoY). Myriad raised the midpoint of full-year 2026 revenue guidance to $780–$790M (from prior range), with Cancer Care Continuum and Mental Health revenue guidance of $620–$630M and Prenatal Health ~$160M. The divestiture is intended to strengthen balance sheet and profitability post-close.
Why this rating
Asset sale worth 43% of market cap (major liquidity event) offsets ongoing revenue headwinds; strategic focus tightening justifies modest premium valuation, though execution risk remains on close.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.